BESPOKE Study of ctDNA Guided Immunotherapy

This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA testing. SIGNATERA test will be performed at baseline and during routine care. The test results will be part of assessing tumor response. The correlation between SIGNATERA test results and subsequent treatment decisions will be examined to compare actual treatment delivered against treatment decisions potentially impacted by SIGNATERA results. Treatment administered, tumor assessment results, time to progression, overall survival, physician questionnaires, and patient-reported outcomes will be collected/recorded.